Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases.
Sign Up to like & getrecommendations! Published in 2022 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2022.2123703
Abstract: BACKGROUND We aimed to compare the efficacy and safety of the original product (OP) and biosimilar product (BP) of adalimumab in pediatric rheumatic diseases. RESEARCH DESIGN AND METHODS The study group consisted of patients who… read more here.
Keywords: efficacy safety; group; adalimumab; biosimilar adalimumab ... See more keywords
THU0552 SWITCH TO BIOSIMILAR ADALIMUMAB - IS IT COST EFFECTIVE?
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.1975
Abstract: Background: Since the introduction of anti-TNF biosimilars in routine clinical practice, there has been a drive to implement the switch program for all biosimilars at the point of availability. First adalimumab biosimilar was granted marketing… read more here.
Keywords: switch; biosimilar adalimumab; disease; support ... See more keywords
THU0157 ‘SWITCH ME IF YOU CAN’ – REAL LIFE EXPERIENCE OF SWITCHING TO BIOSIMILAR DRUGS FROM GARTNAVEL GENERAL HOSPITAL, GLASGOW, UK
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2561
Abstract: Background: Rheumatology has entered the era of biosimilar drugs. Compared with the original approved biological drug, a biosimilar has highly similar physiochemical characteristics and biological activity1. There is also equivalent efficacy and no clinically meaningful… read more here.
Keywords: biosimilar adalimumab; gartnavel general; general hospital; rheumatology ... See more keywords
Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
Sign Up to like & getrecommendations! Published in 2022 at "Medicina"
DOI: 10.3390/medicina58121851
Abstract: Background and Objectives: Real-world evidence should reflect the evidence obtained from controlled trials; therefore, the study aimed to compare biosimilar adalimumab (bADA) to original adalimumab (oADA) in terms of efficacy and safety in a real-life… read more here.
Keywords: national cohort; biosimilar adalimumab; rheumatoid arthritis; efficacy safety ... See more keywords